BACKGROUND

Wilms’ tumor (WT) is an embryonal malignancy of the kidney that affects 1 in 10,000 infants and, like retinoblastoma, is observed in both sporadic and inherited forms. The Wilms’ tumor locus has been mapped at chromosome 11p13 as a tumor suppressor gene which encodes a DNA binding protein with four zinc fingers and a glutamine-proline rich amino-terminus. The Wilms’ tumor protein binds the DNA sequence GGCGGGGCG, a recognition element common to the early growth response (Egr) family of Zn2+ finger transcriptional activators. However, in contrast to Egr transcription factors, WT1 behaves as a transcriptional repressor in transient transfection assays with synthetic promoter constructs.

REFERENCES


chromosomal location


PRODUCT

WT1 (h): 293T Lysate represents a lysate of human WT1 transfected 293T cells and is provided as 100 µg protein in 200 µl SDS-PAGE buffer.

STORAGE

Store at -20°C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

APPLICATIONS

WT1 (h): 293T Lysate is suitable as a Western Blotting positive control for human reactive WT1 antibodies. Recommended use: 10-20 µl per lane.

Control 293T Lysate: sc-117752 is available as a Western Blotting negative control lysate derived from non-transfected 293T cells.

WT1 (F-6): sc-7385 is recommended as a positive control antibody for Western Blot analysis of enhanced human WT1 expression in WT1 transfected 293T cells (starting dilution 1:100, dilution range 1:100-1:1,000).

DATA

For research use only, not for use in diagnostic procedures.